Proteins and Peptides

16 Mar 2017 Shire Receives European Approval for Label Extension of CINRYZE®▼(C1 inhibitor ) to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE
16 Mar 2017 Helmsley Charitable Trust and Akston Biosciences Corporation Announce Partnership to Advance Novel Technology to Treat Type 1 Diabetes
14 Mar 2017 Lung Therapeutics, Inc. Doses First Patient in Phase 1 Clinical Trial of LTI-01 in Australia and New Zealand
09 Mar 2017 ProtoKinetix Announces Start of Phase 1 & Phase 2 Clinical Trials for the use of AAGP™ PKX-001 Treated Islet Cells in the Treatment of Type 1 Diabetes
07 Mar 2017 Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines
04 Mar 2017 Amgen Presents Overall Survival Data From KYPROLIS® (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop
04 Mar 2017 FDA approves first treatment for frequent urination at night due to overproduction of urine
03 Mar 2017 BIOCAD: The first ever biosimilar of interferon beta-1a approved in Russia
02 Mar 2017 Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lupus Nephritis Study
01 Mar 2017 Phase 3 Head-to-Head Trial Showed KYPROLIS® (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade® (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients
01 Mar 2017 Recombinant clotting factor VIII with the name Vihuma® approved
28 Feb 2017 RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137 for Epidermolysis Bullosa in U.S.
28 Feb 2017 La Jolla Pharmaceutical Company Announces Positive Top-Line Results from ATHOS-3 Phase 3 Study of LJPC-501
21 Feb 2017 CohBar, Inc. Announces Positive Results from Preclinical NASH Study of its Lead Drug Candidates
20 Feb 2017 AstraZeneca enters agreement with TerSera Therapeutics for Zoladex in the US and Canada
20 Feb 2017 Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium
17 Feb 2017 Ascendis Pharma A/S Announces Publication of Comprehensive Results from Randomized, Active-Controlled Phase 2 Trial of Once-Weekly TransCon Growth Hormone in Pediatric Patients
17 Feb 2017 Capricor Therapeutics Provides Update on Natriuretic Peptide Program
16 Feb 2017 U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review
16 Feb 2017 Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery
16 Feb 2017 Amicus Therapeutics Presents Additional Positive Preliminary Phase 1/2 Data at WORLDSymposium™ 2017
08 Feb 2017 Patient recruitment completed for phase II trial with glepaglutide for treatment of short bowel syndrome
08 Feb 2017 FDA Approves Amgen's Parsabiv™ (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis
06 Feb 2017 Spyryx Biosciences Announces Successful Completion of Phase 1 Clinical Trial for SPX-101 and Planned Phase 2 Initiation in Cystic Fibrosis During 2017
05 Feb 2017 Intarcia Announces FDA Filing Acceptance of New Drug Application (NDA) for ITCA 650 for the Treatment of Type 2 Diabetes

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing